
Idexx Laboratories company profile
$700.65−0.51%Close 16 Nov 2026 · Market value $54.53B
About Idexx Laboratories
Idexx Laboratories, incorporated in Delaware in 1983, develops, manufactures, and distributes diagnostic products, services, and related instrumentation for the companion animal veterinary, livestock, poultry and dairy, and water testing industries, and also manufactures and sells human medical point-of-care diagnostic products. Its Companion Animal Group offers point-of-care analyzers, SNAP rapid assays, outside reference laboratory services, telemedicine, veterinary practice management software, and diagnostic imaging systems. Its Water segment provides microbiological testing products for drinking, wastewater, and recreational water. Its Livestock, Poultry and Dairy segment provides herd health diagnostic tests and dairy antibiotic residue tests. Customers include veterinarians, government and private laboratories, water utilities, producers, and processors. The company sells directly and through independent distributors and resellers, with a sales presence in the U.S. and in regions including Africa, Asia Pacific, Canada, Europe, and Latin America.
A summary of the business section of the company's latest annual report, filed 20 Feb 2026.
Company facts
| Ticker | IDXX · Nasdaq |
|---|
| Sector | Biotechnology |
|---|
| Industry | Health Care Equipment |
|---|
| Index | S&P 500 |
|---|
| Fiscal year ends | 31 December |
|---|
| Reporting currency | USD |
|---|
| CIK | 874716 |
|---|
| Latest annual report | 10-K, filed 20 Feb 2026 |
|---|
Officers and directors
| Name | Role | Shares owned | Latest Form 4 |
|---|
| Jonathan J. Mazelsky | Executive Chair of the Board · Director | 323K · < 1% | Option exercise, 4 Nov 2026 |
|---|
| Brian P. McKeon | EVP, CFO and Treasurer | 52.7K · < 1% | Option exercise, 14 Feb 2025 |
|---|
| Michael J. Lane | Executive Vice President | 31.4K · < 1% | Open-market sale, 4 Nov 2026 |
|---|
| Lawrence D. Kingsley | Director | 24.1K · < 1% | Option exercise, 4 Sep 2026 |
|---|
| Stuart M. Essig, PhD | Director | 12.0K · < 1% | Option exercise, 6 May 2025 |
|---|
| Andrew Emerson | EVP, CFO and Treasurer | 11.0K · < 1% | Shares withheld for tax, 20 Aug 2026 |
|---|
| Sophie V. Vandebroek, PhD | Director | 11.0K · < 1% | Option exercise, 7 May 2026 |
|---|
| M. Anne Szostak | Director | 8.5K · < 1% | Option exercise, 7 May 2026 |
|---|
| Daniel M. Junius | Director | 6.9K · < 1% | Open-market sale, 4 Nov 2026 |
|---|
| Joseph L. (Jay) Hooley | Director | 522 · < 1% | Grant or award, 30 Oct 2026 |
|---|
| Karen Peacock | Director | 333 · < 1% | Option exercise, 7 May 2026 |
|---|
| FENNELL GEORGE | Executive Vice President | — | Option exercise, 10 Nov 2026 |
|---|
| Underberg Sharon E. | EVP, GC & Corporate Secretary | — | Option exercise, 4 Nov 2026 |
|---|
| Hunt Nimrata | Executive Vice President | — | Open-market sale, 3 Mar 2026 |
|---|
| Erickson Michael G | Executive Vice President | — | Option exercise, 19 Feb 2026 |
|---|
| Smith Martin Alexander | Executive Vice President | — | Option exercise, 14 Feb 2026 |
|---|
| Schreck Michael | Executive Vice President | — | Shares withheld for tax, 14 Feb 2026 |
|---|
| Johnson Michael Perkins | Executive Vice President | — | Option exercise, 14 Feb 2026 |
|---|
Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.
IDXX in the terminal
The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.